Healthcare
Cellectis SA(CLLS)
Live Price
Offline$2.98
-3.25% today
1Y Change
+94.89%
Window
Jun 26, 2025 โ Jun 23, 2026
- Market Cap
- $270.00M
- Revenue Growth
- +76.3%
- EPS Growth
- -65.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 26, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cellectis SA (CLLS) is a Healthcare stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $2.98 and up 94.9% across the available one-year price window (Jun 26, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +76.3%, EPS growth of -65.9%, a dividend yield of 0.0%. What stands out right now is revenue +76.3%, EPS -65.9%, free cash flow -317.7% with operating margin -47.6% and ROIC -17.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CLLS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+76.3% vs +7.6% peer median
Operating Margin
Below sector median
-47.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +76.3% and EPS is at -65.9%, with operating margin around -47.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | -5.7% | -4.7% | -20.8% |
2026 Mar 19, 2026 | -27.9% | -4.0% | -8.3% | +27.0% |
2025 Nov 7, 2025 | +110.0% | +11.3% | +22.3% | +44.8% |
Benchmark Edge
CLLS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLLS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLLS Max Drawdown
-47.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLLS and SPY.
Company Overview
Cellectis SA
NASDAQ
Cellectis S.A. - ADR represents American Depositary Receipts of the French biotechnology company Cellectis S.A. This company specializes in the development of gene-editing technologies, particularly focusing on allogeneic CAR-T cell therapies for the treatment of cancer. Cellectis utilizes its proprietary TALEN (Transcription Activator-Like Effector Nucleases) technology to precisely edit genes, aiming to harness the power of modified immune cells to target and destroy malignancies. Cellectis operates at the cutting edge of biotechnology, playing a pivotal role in the burgeoning field of personalized medicine and immunotherapy. Through partnerships with major pharmaceutical firms and research institutions, Cellectis aims to innovate and refine therapeutic approaches in the oncology sector. The ADRs allow U.S. investors to engage with Cellectis's pioneering activities without the complexities of foreign stock purchase, illustrating the company's commitment to broadening its investor base and support for global biomedical advances. In the financial market, Cellectis S.A. - ADR is significant due to its contributions towards breakthrough cancer therapies and its involvement in a rapidly developing segment of the healthcare industry.
- Leadership
- Dr. Andre Choulika Ph.D.
- Employees
- 216
- Street Address
- 8, rue de la Croix Jarry
- Mailing
- Paris, 75013
- Region
- Paris, France
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.7
- Price/Book
- 4.9
Growth
- Revenue
- +76.3%
- EPS
- -65.9%
- Free Cash Flow
- -317.7%
Profitability
- Gross Margin
- 83.6%
- Operating Margin
- -47.6%
- Net Margin
- -92.9%
- ROE
- -69.6%
- ROIC
- -17.5%
Balance Sheet
- Debt/Equity
- 1.58
- Current Ratio
- 1.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.